BeyondSpring(NASDAQ) BYSI

Market Cap$46.47M

Since IPO (2017)-93%

5 Year-88%

1 Year-44%

1 Month-38%

$1.18

-0.42%

-0.01Today

After hours$1.14-$0.04 (-3.39%)

BeyondSpring last closing stock price
Metric	Price	Date
Last close	USD 1.15	2026-07-31

BeyondSpring stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.68%	USD 1.12	2026-07-24
1 month	-37.84%	USD 1.85	2026-07-01
3 month	-22.82%	USD 1.49	2026-05-01
Year to date	-29.45%	USD 1.63	2025-12-31
1 year	-43.9%	USD 2.05	2025-07-31
3 year	+12.75%	USD 1.02	2023-08-01
5 year	-87.92%	USD 9.52	2021-07-30
Since inception	-93.27%	USD 16.80	2017-03-09

BeyondSpring Financials at a Glance

Market Cap

$46.47M

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.64M

EPS (TTM)

-$0.19

P/E Ratio

-6.01

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$1.18

Volume

8,667

Open

$1.18

Price

$1.18

Volume

8,667

Open

$1.18

Previous Close

$1.15

Daily Range

$1.15 - $1.20

52-Week Range

$0.99 - $2.44

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$1.18

Volume

8,667

Open

$1.18

Previous Close

$1.15

Daily Range

$1.15 - $1.20

52-Week Range

$0.99 - $2.44

Estimated Earnings Date

Aug 12, 2026

BYSI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BeyondSpring

BeyondSpring develops medicines for people with cancer, aiming to reduce side effects and improve treatment. Its main product helps patients avoid dangerous drops in white blood cells during chemotherapy. The company also works on new drugs that target hard-to-treat cancers.

Lab Bench to Bedside: What BeyondSpring Sells

Plinabulin: A drug candidate to prevent low white blood cell counts and treat lung cancer; targets patients undergoing chemotherapy or with advanced cancer.
Combination Therapies: Plinabulin is tested with other cancer drugs, such as immune system boosters, for broader cancer treatment.
Preclinical Immune Agents: Three early-stage drugs designed to help the immune system fight cancer; not yet in human trials.
Targeted Protein Degradation Platform: Through SEED Therapeutics, develops drugs that break down disease-causing proteins in cancer cells.

Growth Spurts and Global Moves

Completed Phase III trial for Plinabulin in lung cancer with final results published in 2024.
Formed partnership with Eli Lilly in 2020 and with Eisai in 2024 for drug discovery and development.
Entered China market through licensing deal with Jiangsu Hengrui Pharmaceuticals in 2021.
Advanced SEED Therapeutics’ lead drug into Phase 1 clinical trials in January 2026.

Why BeyondSpring Stands Out (Without the Lab Coat)

BeyondSpring operates in both the US and China, using global clinical trials to speed up drug development. Its main drug works differently from most cancer medicines, aiming to help patients who do not respond to standard treatments. The company partners with large pharmaceutical firms to share research and reduce costs.

Five Things You Need to Know

Revenue was $0 in QQ3 2025, down 100% from $438,000 in QQ3 2023.
Net loss was $2 million in QQ3 2025, down 586.4% from QQ3 2024.
Cash and equivalents were $7.8 million as of December 31, 2025.
Accumulated deficit reached $408.4 million by December 31, 2025.
Company had 44 full-time employees, mostly in research roles, in early 2026.

Bottom Line

BeyondSpring remains focused on developing new cancer drugs, with no commercial sales yet. Its partnerships and global approach support ongoing research despite financial challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Lan Huang, PhD

Website

www.beyondspringpharma.com

Headquarters

Florham Park, NY 07932, US

BYSI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

23.76%

Return on Capital

N/A

Return on Assets

-41.52%

Earnings Yield

-16.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$46.47M

Shares Outstanding

41.12M

Volume

8.67K

Avg. Volume

24.62K

Financials (TTM)

Gross Profit

-$19.00K

Operating Income

-$8.57M

EBITDA

-$8.02M

Operating Cash Flow

-$19.09M

Capital Expenditure

-$543.00

Free Cash Flow

-$19.09M

Cash & ST Invst.

$7.86M

Total Debt

$246.00K

BeyondSpring Performance Analysis

BeyondSpring annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,351,000	0.0%
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

BeyondSpring sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

BeyondSpring annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.85	-48.2%
2023	2023-12-31	USD -0.54	-36.7%
2024	2024-12-31	USD -0.28	-48.1%
2025	2025-12-31	USD -0.20	-29.3%

BeyondSpring sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-140.7%
Q3	2025-09-30	10.7%
Q4	2025-12-31	-31.5%
Q1	2026-03-31	0.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$19.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$46.47M

N/A

Market Cap/Employee

$1.06M

N/A

Employees

N/A

Net Income

-$2.16M

-148.2%

EBITDA

-$2.14M

+13.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$7.86M

-7.8%

Total Debt

$246.00K

-55.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$246.00K

-18.3%

Return on Assets

-41.52%

N/A

Return on Invested Capital

-1.42%

N/A

Free Cash Flow

-$3.28M

+27.2%

Operating Cash Flow

-$3.28M

+26.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ATYRaTyr Pharma, Inc.

ATYRaTyr Pharma, Inc.$0.49+1.19%

GUTSFractyl Health, Inc.

GUTSFractyl Health, Inc.$0.69-0.72%

HYFTMindWalk Holdings Corp.

HYFTMindWalk Holdings Corp.$1.29-4.44%

CAMPCAMP4 Therapeutics Corporation

CAMPCAMP4 Therapeutics Corporation$3.45-0.58%

BMEABiomea Fusion, Inc.

BMEABiomea Fusion, Inc.$1.17-4.10%

QNCXQuince Therapeutics, Inc.

QNCXQuince Therapeutics, Inc.$23.39+1.56%

DTILPrecision BioSciences, Inc.

DTILPrecision BioSciences, Inc.$6.99-0.14%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About BYSI

What is the current price of BeyondSpring?

BeyondSpring is trading at $1.15 per share.

What is the 52-week range for BeyondSpring?

Over the past 52 weeks, BeyondSpring has traded between $0.99 and $2.44.

How much debt does BeyondSpring have?

As of the most recent reporting period, BeyondSpring reported total debt of $246.00K.

How much cash does BeyondSpring have on hand?

BeyondSpring reported $4.04M in cash and cash equivalents in its most recent financial results.

What is BeyondSpring’s dividend yield?

BeyondSpring does not currently have a dividend yield.

BeyondSpring(NASDAQ) BYSI

BeyondSpring Financials at a Glance

BYSI News

BeyondSpring Cash Jumps in Fiscal Q2

Why BeyondSpring Stock Is Soaring This Week

This Biotech Stock Just Skyrocketed by 170%. Is It a Buy?

Why BeyondSpring Stock Skyrocketed Today

These 2 Soaring Biotech Stocks Are Making the Nasdaq Stronger

Why BeyondSpring Is Plunging Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About BeyondSpring

Lab Bench to Bedside: What BeyondSpring Sells

Growth Spurts and Global Moves

Why BeyondSpring Stands Out (Without the Lab Coat)

Five Things You Need to Know

Bottom Line

BYSI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

BeyondSpring Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BYSI

What is the current price of BeyondSpring?

What is the 52-week range for BeyondSpring?

How much debt does BeyondSpring have?

How much cash does BeyondSpring have on hand?

What is BeyondSpring’s dividend yield?

Premium Investing Services